Magnesium Levels May Predict Peripheral Artery Disease Risk
Higher magnesium levels are associated with a lower risk of peripheral artery disease, but only among individuals without impaired renal function.
|The following article is part of conference coverage from Kidney Week 2018 in San Diego hosted by the American Society of Nephrology. Renal & Urology News staff will be reporting live on medical studies conducted by nephrologists and other specialists who are tops in their field in acute kidney injury, chronic kidney disease, dialysis, transplantation, and more. Check back for the latest news from Kidney Week 2018.|
SAN DIEGO—Serum magnesium levels are associated with the risk of peripheral artery disease (PAD) among individuals without impaired renal function, according to new study findings presented at the American Society of Nephrology's Kidney Week 2018 conference.
Among individuals without renal impairment (estimated glomerular filtration rate [eGFR] of 60 mL/min/1.73 m2 or higher), a serum magnesium value at or above a median value of 1.6 mEq/L was associated with a significant 22% decreased risk of PAD in adjusted analyses, Steven Menez, MD, of Johns Hopkins University in Baltimore, and collaborators reported. The investigators found no significant association between serum magnesium level and PAD among individuals with an eGFR below 60 mL/min/1.73 m2.
For the study, Dr Menez's team used data from 14,276 participants in the Atherosclerosis Risk in Communities (ARIC) Study who were free of PAD at baseline. The study population had a mean age of 54.6 years. Of the 14,276 participants, 14,109 had an eGFR of 60 mL/min/1.73 m2 or higher and 167 had a lower eGFR. Over a median follow-up of 25.9 years, 420 PAD cases were diagnosed.
|Visit Renal & Urology News' conference section for continuous coverage from Kidney Week 2018.|
Menez S, Ding N, Grams M, et al. Serum magnesium levels and subsequent risk of peripheral artery disease. Presented at the American Society of Nephrology's Kidney Week 2018 conference in San Diego, Oct. 23-28. Abstract TH-PO460.